Xylazine: Effects, Wounds, Overdose Response, and Treatment

Xylazine is a non-opioid alpha-2 adrenergic veterinary sedative found as an adulterant in the unregulated drug supply, most often with illegally manufactured fentanyl. It is not approved for human use. Exposure can produce prolonged sedation, slow breathing, low blood pressure, slow heart rate, and wounds, while repeated exposure may contribute to physical dependence.

A xylazine-involved overdose is a medical emergency. Naloxone does not reverse xylazine, but it should be given when opioid co-exposure is possible; emergency services can support breathing, circulation, and other effects that naloxone cannot reverse.

What is xylazine?

Clinical perspective

Xylazine's depressant effects on the central nervous system are a grave concern because the drug is often masked within other substances, posing severe risks due to its potent nature.

Xylazine is a non-opioid sedative and analgesic that activates alpha-2 adrenergic receptors. The FDA first approved xylazine hydrochloride for veterinary use in 1972, and no xylazine product is approved for use in people. Its veterinary role does not establish a safe human dose or a legitimate human medical use.

Xylazine reduces central nervous system activity and can suppress alertness, breathing, heart rate, and blood pressure. It is not an opioid, does not activate opioid receptors, and should not be classified as an opiate or a form of fentanyl.

Why is xylazine found with fentanyl?

Xylazine enters the unregulated drug supply primarily as an adulterant in illegally manufactured fentanyl. A person may encounter the sedative without requesting it or knowing that it is present. The drug's appearance, taste, packaging, and seller description cannot confirm whether a powder or pill contains xylazine.

The DEA's 2025 National Drug Threat Assessment found xylazine much more often in powder fentanyl exhibits than in counterfeit fentanyl pills and documented an upward forensic-laboratory trend during 2020 through 2024. These seizure data describe tested exhibits, not every drug sold or used in the United States. Combining xylazine with illegally manufactured fentanyl can prolong sedation while the opioid continues to suppress breathing.

How common is xylazine in U.S. overdose deaths?

Xylazine appears in thousands of recent U.S. overdose death records, but involvement does not prove that xylazine alone caused each death. CDC National Center for Health Statistics data available on July 5, 2026 reported 2,483 provisional xylazine-involved deaths for the 12 months ending December 2025; the comparable count was 6,109 for the 12 months ending December 2024; both counts can change as records are completed and revised.

Death certificates can list xylazine, fentanyl, cocaine, or several other drugs in the same event. Testing practices also vary by jurisdiction, so the absence of xylazine from a record may mean it was absent, not tested, or not reported. These drug-specific provisional records therefore answer a narrower question than final U.S. drug overdose statistics.

What effects does xylazine cause in humans?

Xylazine depresses the central nervous system and can impair consciousness, breathing, circulation, and temperature regulation. The FDA and CDC identify sedation, respiratory depression, low blood pressure, slow heart rate, and reduced body temperature among reported acute effects.

• Neurologic effects: profound drowsiness, confusion, reduced responsiveness, or coma.
• Respiratory effects: slow, shallow, irregular, or stopped breathing, especially during opioid co-exposure.
• Cardiovascular effects: bradycardia, hypotension, fainting, or inadequate circulation.
• Skin effects: ulcers, devitalized tissue, and wounds that can become infected or expose deeper structures.

These effects overlap with opioid poisoning and other medical emergencies. Symptoms cannot identify xylazine, determine the amount taken, or rule out fentanyl without appropriate testing and clinical assessment.

What are the signs of a xylazine-involved overdose?

A xylazine-involved overdose can cause unresponsiveness, abnormal breathing, a slow pulse, low blood pressure, and persistent sedation after naloxone. Because fentanyl commonly accompanies xylazine, responders should treat inability to awaken or slow, shallow, irregular, or stopped breathing as a possible opioid overdose.

Give naloxone when opioid exposure is possible, call 911, and support breathing or provide CPR if trained and indicated. Naloxone reverses opioid receptor effects; it does not reverse xylazine's non-opioid sedation, so a partial response or no response requires continued emergency support rather than an assumption that help is no longer useful.

No medication is FDA-approved to reverse xylazine in people. The FDA warns that veterinary reversal drugs have not been shown safe or effective for human xylazine poisoning and should not be used as improvised antidotes.

What do xylazine-associated wounds look like?

Xylazine-associated wounds can develop into ulcers with dead tissue, exposed deeper structures, or secondary infection. They commonly affect the arms and legs, and clinicians have documented wounds both at and away from reported injection sites. A wound's appearance alone cannot confirm xylazine exposure because infections, vascular disease, inflammatory disorders, and other conditions can look similar.

A 2025 JAMA Dermatology case series examined 59 wounds in 29 hospitalized patients with xylazine confirmed in urine: 53 wounds (90%) were on extremities, 34 of 57 photographed wounds (60%) contained mostly devitalized tissue, and 5 wounds (9%) exposed bone or tendon. The study described patients at three academic hospitals in Philadelphia and should not be treated as a national wound-prevalence estimate.

The biological mechanism remains unsettled. Repeated xylazine exposure is associated with severe wounds, but current human evidence does not justify claiming that every lesion results from one route, one vascular mechanism, or xylazine alone.

How should xylazine-associated wounds be treated?

Xylazine-associated wounds require prompt clinical evaluation, regular wound care, and treatment of infection or tissue damage when present. CDC guidance recommends early care because untreated wounds can deepen, become infected, threaten a limb, or become life-threatening, while early wounds can often be managed without major surgery.

A clinician should assess wound depth, circulation, pain, infection, exposed tissue, and barriers to follow-up before selecting dressings, debridement, antibiotics, or surgical consultation. Antibiotics may be needed when clinical assessment identifies bacterial infection; they do not treat xylazine exposure itself.

Fever, confusion, rapidly spreading redness or swelling, worsening pain, foul drainage, black tissue, heavy bleeding, or exposed bone or tendon warrants urgent medical assessment. Wound treatment and substance-use care can proceed together; a person does not need to heal completely or achieve abstinence before receiving respectful clinical care.

How is xylazine exposure detected?

Xylazine exposure requires targeted drug checking or specialized laboratory testing because routine toxicology screens usually do not detect it. The FDA states that standard immunoassay screens can miss xylazine and that blood or urine identification may require mass spectrometry or another validated analytical method.

Community xylazine test strips can screen a drug sample for possible presence, but a result does not show concentration, purity, or whether the sample is safe. A negative result can miss xylazine because strip performance, dilution, sampling, interfering substances, and uneven distribution within a batch can change the result.

A 2025 primary study compared one xylazine test strip with mass spectrometry in 85 human urine specimens: sensitivity was 86%, specificity was 93%, and six of 43 mass-spectrometry-positive specimens produced false-negative strip results. The authors concluded that the strip needed further refinement, and the product lacked regulatory approval for testing human specimens.

Can repeated xylazine exposure cause dependence or withdrawal?

Repeated xylazine exposure may cause physiological dependence, but a distinct human xylazine withdrawal syndrome has not been established. Anxiety, agitation, sweating, tremor, elevated blood pressure, and a fast heart rate have been reported after exposure stops, yet opioid, alcohol, benzodiazepine, and stimulant effects can produce overlapping symptoms.

A 2025 retrospective cohort evaluated 73 hospitalized patients with xylazine-positive urine: 54 patients (74.0%) had no distinct candidate syndrome, 12 (16.4%) were indeterminate, and 2 (2.7%) had a course considered possibly consistent with xylazine withdrawal. Five critically ill patients could not be assessed, so the study narrows the evidence without proving that withdrawal never occurs.

People who feel ill after reducing an unregulated opioid supply need clinical assessment rather than a self-diagnosis. The evaluation should identify opioid withdrawal, sedative or alcohol withdrawal, infection, dehydration, pregnancy, psychiatric symptoms, and cardiovascular instability because each finding changes treatment.

How are xylazine exposure and recovery treated?

Treatment addresses xylazine toxicity, wounds, co-occurring substance use disorders, and recovery needs rather than assuming a standalone diagnosis from exposure alone. Emergency clinicians support breathing and circulation; wound clinicians protect tissue and treat complications; addiction clinicians diagnose every substance-use condition that requires continuing care.

No medication has an FDA-approved indication for xylazine withdrawal. Methadone, buprenorphine, and naltrexone treat opioid use disorder; they do not reverse xylazine or directly treat its non-opioid effects. These medications should still be offered when opioid use disorder is present because untreated OUD leaves the underlying fentanyl exposure and overdose risk unaddressed.

A structured opioid addiction treatment program can coordinate medication, counseling, wound-care follow-up, overdose planning, and recovery support after emergency stabilization. Treatment intensity should reflect medical stability, withdrawal risk, wound severity, psychiatric symptoms, home support, and the person's ability to participate safely.

How can xylazine-related harm be reduced?

Xylazine-related harm is reduced by planning for an unpredictable drug supply, preventing solitary overdose, carrying naloxone, and seeking wound care early. These measures cannot make an unregulated product safe, but they can create time for treatment and reduce preventable complications.

• Prevent an unwitnessed emergency: avoid using alone and arrange for someone who can call 911 and give naloxone.
• Prepare for opioid co-exposure: keep naloxone available and make sure nearby people know where it is and how to use it.
• Reduce infection risk: use sterile equipment, avoid sharing supplies, and obtain clinical care when any wound appears or changes.
• Use drug checking carefully: test services can identify some unexpected contents, but no result verifies dose, purity, or safety.
• Treat the continuing risk: medication for opioid use disorder, behavioral care, and recovery support can reduce repeated exposure to an unpredictable opioid supply.